Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323744 | 1.00 | CNR1 (0.49) | CNR1CASP2EPHX1MEN1KMT2A | |
| SCHEMBL15131732 | 0.90 | MEN1 (0.52) | CNR1CASP2EPHX1MEN1KMT2A | |
| SCHEMBL28340443 | 0.85 | CNR1 (0.68) | CNR1MEN1KMT2AEPHX2 | |
| SCHEMBL5327032 | 0.84 | CNR1 (0.53) | CNR1CASP2EPHX1MEN1KMT2A | |
| SCHEMBL5327026 | 0.84 | CNR1 (0.53) | CNR1CASP2EPHX1MEN1KMT2A | |
| SCHEMBL15257769 | 0.83 | NAAA (0.49) | CNR1CASP2MEN1KMT2ANAAA | |
| SCHEMBL19661057 | 0.83 | MEN1 (0.45) | CNR1CASP2EPHX1MEN1KMT2A | |
| SCHEMBL15131734 | 0.82 | SLC6A5 (0.55) | CNR1CASP2MEN1KMT2ANAAA | |
| SCHEMBL13562877 | 0.82 | CNR1 (0.61) | CNR1MEN1KMT2A | |
| SCHEMBL13562881 | 0.80 | CNR1 (0.42) | CNR1MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486428-B2 | Compositions and methods for making and using acyclic N-halamine-based biocidal polymeric materials and articles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2007126775-A2 | COMPOSITIONS AND METHODS FOR MAKING AND USING ACYCLIC N-HALAMINE-BASED BIOCIDAL POLYMERIC MATERIALS AND ARTICLES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070224161-A1 | Compositions and methods for making and using acyclic N-halamine-based biocidal polymeric materials and articles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224161-A1 | Compositions and methods for making and using acyclic N-halamine-based biocidal polymeric materials and articles | NAAA, NIT2, AADAC | CNR1 1301/4885CASP2 962/4885EPHX1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.